

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

IMMUNOMEDICS INC
Form 8-K
April 08, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 8, 2004

Immunomedics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

000-12104

61-1009366

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

300 American Road, Morris Plains, New Jersey

07950

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (973) 605-8200

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

On April 8, 2004, Immunomedics, Inc. and Amgen Inc. announced that Amgen has returned to Immunomedics all rights for epratuzumab, the humanized CD22 monoclonal antibody therapeutic licensed to Amgen by Immunomedics in December 2000, including rights to second generation molecules and conjugates. A copy of the press release announcing this information is attached to this report as Exhibit 99.1 hereto and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits:

99.1 Press Release issued by Immunomedics, Inc. and Amgen Inc.
on April 8, 2004.

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: April 8, 2004

IMMUNOMEDICS, INC.

By: /s/ Cynthia L. Sullivan

Name: Cynthia L. Sullivan

Title: President and Chief Executive Officer

EXHIBIT INDEX

99.1 Press Release issued by Immunomedics, Inc. and Amgen Inc. on
April 8, 2004.